Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study

<p><strong>BACKGROUND:</strong> A new formulation of the live-attenuated varicella vaccine Varilrix (GSK) produced without human serum albumin (HSA) was developed to minimize a theoretical risk of transmission of infectious diseases. A previous study showed that the vaccine was imm...

Full description

Bibliographic Details
Main Authors:	Faust, SN, Le Roy, M, Pancharoen, C, Weber, MAR, Cathie, K, Behre, U, Bernatoniene, J, Snape, MD, Helm, K, Pech, CE, Henry, O, Baccarini, C, Povey, M, Gillard, P
Format:	Journal article
Language:	English
Published:	BioMed Central 2019

Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study

Similar Items